Weekly Recap | WuXi Biologics +0.15%, closing in on record highsWeekly Review·Aug 29 at 06:38 AMWXXWY-1.02%
CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGeneUnusual Whales·Aug 28 at 11:13 AM
CSPC wins China clinical trial approval for SYH2092 amylin agonist injectionPUBT·Aug 27 at 10:19 AM01093+3.93%
Chase Sun Pharmaceuticals released its performance for the first three quarters, with a net profit attributable to the parent company of 80.7629 million yuan, a decrease of 52.03%Zhitong·Oct 28, 2025 at 01:16 PM300026-0.90%
Chase Sun Pharmaceuticals released its performance for the first half of the year, with a net profit attributable to the parent company of 78.63 million yuan, a decrease of 46.95%Zhitong·Aug 27, 2025 at 08:09 AM300026-0.90%
The traditional Chinese medicine concept continues to strengthen, with Layn hitting the daily limit, and companies such as Zhongsheng Pharmaceutical, Kanion Pharmaceutical, JINGXIN, Zhendong Pharmacy, CONBA, and Chase Sun also risingZhitong·Aug 12, 2025 at 01:36 AM600572-0.45%300026-0.90%
Chase Sun Pharmaceuticals released its first-quarter performance, with a net profit attributable to the parent company of 60.3297 million yuan, an increase of 3.80%Zhitong·Apr 27, 2025 at 10:51 AM300026-0.90%
Hubei Chenmei Traditional Chinese Medicine signed agreements with multiple parties to jointly promote the high-quality development of the entire industrial chain of Dabieshan authentic medicinal materialsZhitong·Apr 2, 2025 at 01:56 PM300026-0.90%
Chase Sun: Delay in the disclosure of the 2024 annual reportZhitong·Mar 24, 2025 at 09:25 AM300026-0.90%
Chase Sun Pharmaceutical's injectable Labetalol hydrochloride has obtained the drug clinical trial approvalZhitong·Mar 21, 2025 at 09:13 AM300026-0.90%
Chase Sun's net profit for the year 2024 is 51.052 million yuan, a year-on-year decrease of 89.92%Zhitong·Feb 27, 2025 at 08:58 AM300026-0.90%
Chase Sun Pharmaceuticals issued a profit warning, expecting a net profit of 48 million to 62 million yuan for the fiscal year 2024, a year-on-year decrease of 90.53% to 87.76%Zhitong·Jan 20, 2025 at 12:54 PM300026-0.90%
Chase Sun's shareholder Yao Xiaoqing plans to reduce holdings by no more than 2.56% of sharesZhitong·Dec 23, 2024 at 12:29 PM300026-0.90%
